Originally published In Press as doi:10.1074/jbc.M111902200 on February 26, 2002
J. Biol. Chem., Vol. 277, Issue 20, 17406-17414, May 17, 2002
c-SRC Mediates Neurite Outgrowth through Recruitment of Crk
to the Scaffolding Protein Sin/Efs without Altering the Kinetics of
ERK Activation*,
Liang-Tung
Yang
,
Konstantina
Alexandropoulos§, and
Jan
Sap
¶
From the
Department of Pharmacology, New York
University School of Medicine, New York, New York 10016 and
§ Department of Pharmacology, College of Physicians and
Surgeons, Columbia University, New York, New York 10032
Received for publication, December 13, 2001, and in revised form, February 20, 2002
 |
ABSTRACT |
SRC family kinases have been consistently and
recurrently implicated in neurite extension events, yet the mechanism
underlying their neuritogenic role has remained elusive. We report that
epidermal growth factor (EGF) can be converted from a non-neuritogenic
into a neuritogenic factor through moderate activation of endogenous SRC by receptor-protein-tyrosine phosphatase
(a physiological SRC
activator). We show that such a qualitative change in the response to
EGF is not accompanied by changes in the extent or kinetics of ERK
induction in response to this factor. Instead, the pathway involved
relies on increased tyrosine phosphorylation of, and recruitment of Crk
to, the SRC substrate Sin/Efs. The latter is a scaffolding protein
structurally similar to the SRC substrate Cas, tyrosine
phosphorylation of which is critical for migration in fibroblasts and
epithelial cells. Expression of a dominant negative version of Sin
interfered with receptor-protein-tyrosine phosphatase
/EGF- as well
as fibroblast growth factor-induced neurite outgrowth. These
observations uncouple neuritogenic signaling in PC12 cells from
sustained activation of ERK kinases and for the first time identify an
effector of SRC function in neurite extension.
 |
INTRODUCTION |
Most analyses that use reductionist systems such as PC12 cells to
identify pathways governing neuronal process formation have focused on
the Ras/ERK1 pathway, the
requirement of which is well established. The neuritogenic effect of
constitutively active MEK has been taken to indicate that ERK
activation is also sufficient for neuritogenesis. Yet, physiological
ERK activation, e.g. in response to EGF, often does not
engender neurite extension. An attempt to resolve this paradox has been
the postulate that the kinetic pattern of ERK signaling after a
stimulus is what dictates the nature of the ensuing response (1). In
this view, "sustained" activation of ERK (hours), such as typically
seen for FGF or NGF, would be the signal that specifies a neuritogenic
outcome as opposed to the "transient" (<1 h) ERK induction
associated with non-neuritogenic factors such as EGF. However, such a
correlation does not necessarily imply sufficiency or necessity.
Diverse and independent approaches have exposed the necessity of
postulating pathways to process formation other than ERK. Recurrently,
tyrosine kinases of the SRC family (SFKs) have been proposed as
candidates for such "parallel pathways." A mutation in Trk retains
ERK induction but abolishes neurite outgrowth by NGF (2). Analysis of
platelet-derived growth factor receptor mutants showed that sustained
ERK activation per se is insufficient but that
neuritogenesis requires additional signals possibly involving SRC (3).
v-SRC induces neurite outgrowth in PC12 cells (4), whereas c-SRC
inhibition can block outgrowth (5, 6). This crucial role of SFKs in
neurite extension is not restricted to PC12 cells but is equally
clearly encountered in conditionally immortalized (7) and primary
neurons (8, 9). SFKs associate with adhesion molecules that facilitate
process elongation (10, 11) and are enriched in nerve growth cones,
where they interact with the cytoskeleton in a protein-tyrosine
phosphatase (PTP)-dependent manner (12).
In fibroblasts and epithelial cells, SRC is intimately implicated in
phosphorylation of focal adhesion proteins, turnover of these
structures, and cell motility (13, 14). v-SRC can activate or inhibit
ERK kinases, depending on the cell type and stage of transformation
(15, 16). Its action as a transforming oncogene can be separated from
its ability to activate Ras and ERK (17, 18). One of the major SRC
substrates, Cas, in complex with the adaptor Crk, is a key mediator of
cell migration in fibroblasts and epithelial cells (19-23). By
contrast, in neuronal cells, the identity of signaling steps downstream
of c-SRC has remained obscure. One reason for this lack of progress has
been the previous extensive reliance on mutationally activated v-SRC.
Given the drastic degree of kinase activation and deregulation of the
latter, this approach has not been informative regarding the function
of endogenous c-SRC. Indeed, the signaling pathways downstream of
oncogenic and cellular SRC proteins were recently shown to differ
substantially; for instance, c-SRC-mediated activation of certain
promoters relies exclusively on Rap1, whereas transforming SRC alleles
also signal through Ras (24). Approaches using oncogenic SRC alleles
are particularly compromised by the experimental difficulty of
separating the biological effect of mutationally activated v-SRC from
its ability to deregulate ERK kinases (15, 16).
SFKs are regulated by a conformational mechanism that is controlled by
phosphorylation. Intramolecular interactions between the SH2 domain and
a C-terminal tyrosine phosphorylation site (Tyr-527 in chicken SRC) in
combination with SH3-mediated interactions stabilize a kinase-inactive
conformation (25). In consequence, wild type SRC family kinases are
reversibly activated in situ by ligands to their SH2 and SH3
domains (24, 26, 27) or by PTPs that mediate Tyr(P)-527
dephosphorylation (28). Extensive evidence identifies receptor-PTP
(RPTP
) as one such physiological Tyr(P)-527 phosphatase. This PTP,
which is particularly abundant in neural tissue, associates physically
with SRC and Fyn (26, 29, 30), and its overexpression activates these
kinases (26, 29-32); conversely, loss of RPTP
leads to
dose-dependent reductions in SRC and Fyn kinase activities
and generates integrin signaling deficits similar to
SRC
/
cells (33, 34). RPTP
itself undergoes tyrosine
phosphorylation at a residue (Tyr-798) in its C terminus. This
modification leads to Grb2 recruitment (35, 36) and alters RPTP
function (36), SRC-activating ability (26), and localization (37). In
the present study, we have exploited the role of RPTP
as a
physiological SRC activator to identify signaling events downstream of
SRC in neuronal cells.
 |
MATERIALS AND METHODS |
Cell Culture--
PC12 cells were cultured in Dulbecco's
modified Eagle's medium plus 10% fetal calf serum and 10% horse
serum. Retrovirus production and infection were as described (36). For
neuritogenesis, 5 × 104 cells were seeded per 35-mm
plate, grown overnight, and starved (0.5% fetal calf serum plus 0.5%
horse serum) for 16-20 h. To this medium was then added 50 ng/ml
acidic FGF plus 5 µg/ml heparin or 100 ng/ml EGF.
Data Analysis--
After 2 days of stimulation, neurite length
was measured on photographed fields containing 100-250 cells. Data
were expressed in two ways; first, as total neurite length averaged
over cell number (bar diagrams; y axis = cell
diameters); second, as percent neurite-bearing cells (percent cells
bearing at least one neurite larger than two cell diameters). The level
of statistical significance was assessed by a two-sided t
test (unequal variance). In bar diagrams, error bars always indicate
95% confidence intervals. For numerical data (% neurite-bearing
cells), the extent of a 95% confidence interval is indicated by the
number between brackets. All key conclusions were re-confirmed on
independent clones and/or pools of clones selected en
masse.
Antibodies and Plasmids--
Anti-RPTP
(36), and anti-Sin
(38) sera have been described. Anti-SRC was from Calbiochem. For the
immunoprecipitation/in vitro ERK assay and immunoblotting,
anti-ERK-1 C-16 and anti-ERK2 C-14 (Santa Cruz) were used,
respectively; anti-phospho-ERK antibody was from New England
Biolabs. Anti-phosphotyrosine antibody 72 was described (36);
4G10 was from Upstate Biotechnology. Anti-Cas was a gift of T. Parsons
and A. Bouton (University of Virginia). Anti-CrkL C-20 was from Santa
Cruz. Anti-Nck sera were provided by E. Skolnik (New York University)
or from Santa Cruz (C-19).
RPTP
constructs were described (36). The Sin deletion SinSD, lacking
residues 101-256 (38), was generated using the Exsite kit
(Stratagene). Two retroviral vectors were used: pLXSHD (36), and
pBabeI-EG (D. Unutmaz, NYU). The latter encodes an long terminal repeat-driven di-cistronic transcript consisting of the
transduced cDNA and green fluorescent protein (3' to an internal
ribosomal entry site). cDNA inserts were ligated between
XhoI and BamHI of pLXSHD or into the
BamHI site of pBabeI-EG.
Immunoprecipitation and Immunoblotting--
Lysates in 50 mM Hepes, pH 7.5, 1% Triton X-100, 150 mM
NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10%
glycerol, 1 mM Na3VO4, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, and 10 µg/ml aprotinin were cleared at 16,000 × g for 15 min, and equal amounts of protein were
immunoprecipitated with antibodies conjugated to protein A-Sepharose
for 2 h at 4 °C. SDS-PAGE-separated proteins were transferred
to nitrocellulose and subjected to immunoblotting followed by ECL or
125I-autoradiography.
Immunofluorescence--
Cells on collagen-coated
coverslips were fixed (4% paraformaldehyde/phosphate-buffered saline,
20 min) and permeabilized (0.1% Triton X-100, phosphate-buffered
saline, 20 min). They were blocked in phosphate-buffered saline plus
10% fetal calf serum for 30 min and incubated with primary antibody
for 1 h followed by 10 µg/ml secondary antibody and examined
under a Zeiss photomicroscope.
In Vitro Kinase Assays--
For SRC assays, cells were lysed in
radioimmune precipitation buffer (50 mM Hepes, pH 7.4, 1%
deoxycholic acid, 1% Triton X-100, 0.1% SDS, 150 mM NaCl,
1 mM EGTA) plus protease and PTP inhibitors. Anti-SRC
precipitates were washed 3× in radioimmune precipitation buffer
and twice in TBS (150 mM NaCl, 20 mM Tris, pH
7.5) and split for anti-SRC immunoblotting and kinase assay. Enolase
substrate was denatured in 50 mM sodium acetate at 30 °C
for 5 min and neutralized with 1 M Tris-HCl, pH 7.5. Reactions (50 µl) in kinase buffer (20 mM Tris, pH 7.5, 5 mM MnCl2) contained 12.5 µg of enolase plus
10 µCi of [
-32P]ATP and were incubated at 30 °C
for 10 min.
ERK1 assays involved precipitation from Triton lysate and incubation in
25 µl of buffer (10 mM Tris, pH 7.3, 10 mM
MgCl2) with 10 µCi of [
-32P]ATP plus
12.5 µg of myelin basic protein for 25 min at 30 °C. Reactions were stopped by SDS-PAGE sample buffer, and gel
autoradiographs were quantitated using phosphorimaging.
 |
RESULTS |
EGF Induces Neurite Outgrowth in c-SRC-overexpressing PC12
Cells--
v-SRC induces growth factor-independent neuritogenesis in
PC12 cells (4), but how this may relate to the physiological function
of c-SRC is poorly understood. We used retroviral infection to generate
a pool of PC12 cells overexpressing c-SRC (Fig.
1A). This conferred upon EGF
(normally a solely mitogenic factor (1)) an ability to induce
neurite formation equal to that of a bona fide neuritogenic
factor (FGF) in control cells (Fig. 1C). This suggests that
an SRC-dependent function can contribute to converting a
non-neuritogenic factor (EGF) into a neuritogenic one. Increases in
tyrosine phosphorylation after c-SRC overexpression were largely limited to four proteins of 130, 90, 70, and 60 kDa (the latter being
SRC itself) (Fig. 1B).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
SRC expression allows neurite outgrowth in
response to EGF. PC12 cells were infected with an SRC-encoding or
control retrovirus, and lysates were analyzed by anti-SRC
(A) or anti-phosphotyrosine (B) immunoblotting
(IB). C, neurite formation in the absence or
presence of EGF or FGF. Data are expressed as averaged neurite
length/cell (bar diagram; y axis = cell
diameters) or as % neurite-bearing cells (% n, numbers
below diagram = % of cells bearing a neurite larger than two cell
diameters). 95% confidence intervals are indicated by error
bars (in the bar diagram indicating neurite lengths) or by the
numbers between brackets (next to numbers below
indicating % neurite bearing cells). Statistical significance is
tested with respect to unstimulated control PC12 cells or to
unstimulated c-SRC expressing cells (*, p < 0.05; **,
p < 0.01; ***, p < 0.001).
|
|
RPTP
Localizes to Cell-Cell Contact Zones and Tips of
Spontaneous Spikes and Activates Endogenous SRC--
To ask whether
endogenous levels of c-SRC could similarly contribute to conversion of
EGF into a neuritogenic factor, we relied on the known c-SRC-activating
function of RPTP
(26, 29, 31-34). We previously reported generation
of PC12 lines expressing wt or mutant RPTP
(36). The mutants used
were RPTP
CCSS, catalytically inactive due to mutation of the active
site cysteine residues in either PTP domain (Cys-442, Cys-732) to
serine, and RPTP
Y798F, in which Tyr-798, the site of tyrosine
phosphorylation in RPTP
, was mutated to phenylalanine (resulting in
loss of Grb2 recruitment but normal in vitro catalytic
activity (35)). Immunofluorescence revealed RPTP
was
membrane-localized and concentrated in cell-cell contact zones and at
the tips of spontaneous spikes (Fig.
2A); no significant
differences were seen in localization of wt versus mutant
proteins (not shown).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 2.
Activation of endogenous SRC after expression
of wt RPTP and
RPTP Y798F in PC12 cells. A,
intracellular localization of RPTP by immunostaining. The
arrows point to localization at ends of spontaneous
extensions. B, SRC kinase assay. Lysates were subjected to
anti-SRC immunoprecipitation (IP), and precipitates were
split in two. One-half was subjected to in vitro SRC kinase
assay using enolase as exogenous substrate (top); the other
half was analyzed by anti-SRC immunoblotting (IB).
|
|
wt RPTP
and RPTP
Y798F, but not RPTP
CCSS, moderately increased
c-SRC activity (by 2-fold), with the level of c-SRC protein remaining
unchanged (Fig. 2B). This increase in specific activity likely reflects the well documented ability of RPTP
to reduce the
phosphorylation level of the Tyr-527 residue in c-SRC (33, 34).
Contrasting with the situation for c-SRC-overexpressing cells, we
observed no constitutive effects of RPTP
on cell morphology or on
neurite extension in the absence of added growth factors (data not
shown and Fig. 3B).

View larger version (73K):
[in this window]
[in a new window]
|
Fig. 3.
RPTP causes SRC- and
MEK-dependent neurite outgrowth in response to EGF, and
this effect is potentiated by mutation of the Tyr-798 phosphorylation
site in RPTP . PC12 clones (control or
expressing wt RPTP , RPTP CCSS (catalytically inactive), or
RPTP Y798F (lacking the Tyr-798 phosphorylation site in RPTP ))
were exposed to EGF or FGF for 48 h in the absence or presence of
the MEK inhibitor PD98059 (10 µM) or the SRC inhibitor
PP1 (1 µM). The inhibitory effects of wt RPTP and
stimulatory effect of RPTP Y798F on FGF-induced neuritogenesis were
described previously (36) and are included here as controls.
A, neurite outgrowth data measured over 100-250 cells. Data
and 95% confidence intervals are expressed as described under
"Materials and Methods" and in the legend of Fig. 1 (histogram = average neurite length; numbers = fraction of neurite-bearing
cells). The level of statistical significance was determined by a
two-sided t test with respect to stimulated vector
(V; control) cells (i.e. left bar in
each graph) (*, p < 0.05; ***, p < 0.001).
B, photographs of representative fields after EGF treatment
in the absence or presence of the indicated inhibitors.
|
|
RPTP
Stimulates EGF-induced Neurite Outgrowth in a Manner That
Requires Both SRC and ERK--
As reported previously (36), the
presence of wt RPTP
, but not catalytically inactive RPTP
CCSS,
impairs the ability of FGF (and NGF; data not shown) to cause neurite
outgrowth. Mutation of the Tyr-798 phosphorylation site in RPTP
not
only abolishes, but inverts this effect of wt RPTP
, since
RPTP
Y798F behaves instead as a net potentiator of FGF-induced
outgrowth (36) (Fig. 3A, right panel).
We here report that, unexpectedly, the effect of wt RPTP
on
responsiveness to EGF was the opposite of that on FGF responsiveness; that is, wt RPTP
converted EGF into a promoter of neurite
outgrowth (Fig. 3A, left panel). Furthermore,
RPTP
Y798F promoted neurite outgrowth in response to EGF even more
powerfully than wt RPTP
(Fig. 3A, left panel).
In contrast, RPTP
CCSS did not potentiate EGF responsiveness; this
catalytically inactive protein even somewhat reduced the formation of
short spikes that occurs in response to EGF. It is conceivable that
this weak inhibitory effect of RPTP
CCSS reflects dominant
negative-like interference with the function of endogenous RPTP
or
of a related RPTP. However, to what extent C-to-S mutant PTPs can
indeed be relied on to be specific and true dominant-negatives is as
yet still unclear; hence, interpretation of the significance of this
observation is probably premature. Assessment of mRNA levels by
Northern blotting for the metalloprotease transin, a late marker
for NGF-induced neuronal differentiation of PC12 cells (39, 40),
revealed that the EGF-induced neurite extension correlated fully with
expression of this marker. EGF treatment lead to transin induction in
cells expressing wt RPTP
or RPTP
Y798F but not RPTP
CCSS;
moreover, this effect was stronger in RPTP
Y798F than in wt
RPTP
-expressing cells (supplemental data included in the on-line
version of manuscript). This indicates that EGF induced not merely
morphological effects but also changes in gene expression.
The ability of RPTP
to confer outgrowth-promoting activity on the
previously non-neuritogenic EGF is reminiscent of c-SRC overexpression,
although less drastic, since the effect of RPTP
remained fully
EGF-dependent (Fig. 1C versus Fig. 3,
A and B, and data not shown). Pharmacological SRC
inhibition using PP1 abolished the neuritogenic effect of RPTP
and
RPTPY
798F on stimulation with EGF, whereas cell morphology and
viability remained unaffected (Fig. 3B), indicating that the
stimulatory effect of RPTP
on EGF-induced neuritogenesis depends on
the activity of a SFK. At the same time, EGF-induced neurite outgrowth
still continued to be dependent on ERK activity, as shown by
application of PD98059 (a selective MEK1 inhibitor) (Fig.
3B). We did observe a tendency of EGF-stimulated
RPTP
Y798F-expressing cells to still form "stumps" in the
presence of 10 µM PD98059. However, <2% of cells formed protrusions longer than 2 cell diameters, and any protrusions formed
were <1 cell diameter. The number of these protrusions could be
reduced significantly by raising the concentration of PD98059 to 25 µM (data not shown). Hence, these protrusions cannot be
referred to as neurites, and their true biological significance is
questionable at best.
Conversion of EGF into an Outgrowth-promoting Factor by RPTP
Is
Not Accompanied by Alteration in ERK Kinetics--
A widely cited
model traces back the divergent effects of EGF versus FGF on
normal PC12 cells to differences in their kinetics of ERK activation.
It has been proposed that the relatively transient ERK activation
induced by EGF is insufficient for neuritogenesis, which would require
the more sustained (>2 h) activation of ERK that is observed for NGF
or FGF. This hypothesis was prompted by observations that experimental
induction of neurite formation by overexpression of many signaling
molecules is invariably accompanied by a shift in ERK activation
kinetics from a transient to a sustained mode (1). Hence, we wished to
determine whether the ability of wt RPTP
and RPTP
Y798F to convert
EGF into a neuritogenic factor could similarly be accounted for by an
alteration, from transient to sustained, in the kinetics of EGF-induced
ERK activation.
We observed that wt RPTP
inhibited ERK activation in response to FGF
at both the 5-min and 6-h time points, with wt RPTP
more potent at
reducing ERK activation than RPTP
CCSS and RPTP
Y798F (Fig.
4A), suggesting that optimal
inhibition required both catalytic activity and Grb2 binding. Although
reduced ERK activation might explain the ability of wt RPTP
to
inhibit FGF-induced neurite formation (Fig. 3A), this
correlation broke down for RPTP
Y798F, which reduced ERK activation
by FGF (Fig. 4A and data not shown) but enhanced neurite
extension induced by this factor (Fig. 3A).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
RPTP
decreases ERK activation in response to acidic
FGF but does not affect the extent and kinetics of ERK activation in
response to EGF. A and B, relative ERK
activity at various time points as determined by in vitro
ERK kinase assay. A representative autoradiograph is shown in
A. ERK activities in response to FGF relative to the vector
control were 0.4 (wt), 0.5 (CCSS), and 0.6 (YF) at 5 min and 0.4 (wt),
0.6 (CCSS), and 0.6 (YF) at 6 h. Quantitation and statistical
analysis of 3 independent experiments is shown in B. Error bars denote 95% confidence intervals.
Statistical significance was tested by a two-sided t test
with respect to EGF-stimulated empty vector-infected (control) cells
(i.e. left column in each graph) (*, p < 0.05). C, lysates from clones exposed to EGF for the
indicated times were analyzed by immunoblotting with an antibody
against activated (phosphorylated) ERK1/2. For each time point,
vector-infected (V, control) cells were also stimulated
with acidic FGF as a positive control. MBP,
myelin basic protein.
|
|
The situation in the case of EGF was analyzed in extensive detail. As
expected from the literature (1), in control cells, EGF- and
FGF-induced ERK activities were comparable at the 5-min time point but
differed significantly at later time points, with FGF-induced
activation sustained longer (Fig. 4, A-C). Strikingly, however, neither wt RPTP
nor RPTP
Y798F (which both potentiate EGF-induced neurite outgrowth; see Fig. 3) potentiated the extent of
ERK induction by EGF. In the short term (5 min), expression of wt or
mutant RPTP
actually tended to reduce ERK activation (Fig.
4B, left panel). More importantly, none of the wt
or mutant RPTP
proteins significantly altered EGF-induced ERK
activation at the late time point (6 h) (Fig. 4B,
right panel). As expected from the literature (1), in the
control (vector) cells at late time points, EGF-induced ERK activation
was significantly lower than FGF-induced activation (Fig.
4B, right panel, and C). Similar conclusions regarding the effect of RPTP
on ERK activation were reached by in vitro kinase assay (Fig. 4B) and by
immunoblotting with phospho-specific antibodies for the activated state
of ERK 1 and 2 (Fig. 4C).
We conclude that wt RPTP
and RPTP
Y798F counteract the induction
of ERK by FGF but do not alter the extent or kinetics of ERK activation
in response to EGF. This breakdown of the correlation between neurite
outgrowth and the extent of sustained ERK induction leaves the ability
of wt RPTP
and RPTP
Y798F to induce a neuritogenic response to EGF unexplained.
RPTP
in a SRC-dependent Manner Elevates Tyrosine
Phosphorylation of the Docking Proteins Cas and Sin--
In a search
for alternative explanations for conversion of EGF into an
outgrowth-promoting factor, we assessed how RPTP
affected cellular
tyrosine phosphorylation. We found that wt RPTP
and RPTP
Y798F
(but not RPTP
CCSS) specifically elevated tyrosine phosphorylation of
a 90-kDa protein and also caused a more modest increase in a 130-kDa
species (Fig. 5A). This
pattern is similar to that observed after an increase in c-SRC
expression (Fig. 1B). EGF or FGF did not affect the
phosphotyrosine content of these 90- and 130-kDa proteins, and wt or
mutant RPTP
did not alter the overall patterns of tyrosine
phosphorylation induced in response to EGF or FGF (not shown).

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 5.
RPTP elevates
tyrosine phosphorylation of Sin and Cas in a SRC-dependent
manner and enhances complex formation with Crk and Nck.
A, equal amounts of lysate from clones infected with
control, wt, or mutant RPTP -expressing virus were analyzed by
anti-phosphotyrosine (P-Tyr) immunoblotting. Proteins
migrating at 130 and 90 kDa are indicated. B, equal amounts
of total lysate from vector-infected (V) or
RTPT -expressing cells (Wt) were subjected to anti-Sin
(left panels) or anti-Cas (right panels)
immunoprecipitation. In lanes marked IP, the immune
precipitates were split into two portions. One portion was
immunoblotted with anti-phosphotyrosine (upper panels), and
the other was immunoblotted with anti-Sin (lower panel,
left) or anti-Cas (lower panel,
right). In lanes marked SUP, aliquots
of lysates collected before (bfIP) or after
immunoprecipitation (afIP) with the respective antibodies
were analyzed by immunoblotting with the antibodies indicated on the
left. C, lysates were subjected to immunoprecipitation with
anti-CrkL or anti-Nck, and immune precipitates were analyzed by
immunoblotting with anti-Cas, -Sin, -CrkL, and -Nck. D,
anti-Sin immune precipitates were prepared from control cells
(V) or cells expressing wt RPTP (WT) or
RPTP Y798F (YF) treated or not with the SRC inhibitor PP1
(1 µM) for 30 min before lysis. Precipitates were
analyzed by anti-phosphotyrosine (top) or anti-Sin
(bottom) immunoblotting. E, anti-CrkL
precipitates were prepared from control cells (V) or cells
expressing wt RPTP (WT) treated or not with the SRC
inhibitor PP1 (1 µM) for 30 min before lysis.
Precipitates were analyzed by immunoblotting with anti-Sin
(top), anti-Cas (middle), and anti-CrkL
(bottom).
|
|
In trying to characterize these proteins, we found (data not shown)
that RPTP
had not affected phosphorylation of cortactin and Cbl
(both SRC substrates) or of FRS-2 (implicated in
FGF-dependent PC12 differentiation). However, we
successfully identified the proteins whose tyrosine phosphorylation
level was elevated by RPTP
as Sin (90 kDa) and Cas (130 kDa) (Fig.
5, B and D), 2 related docking proteins and known
SRC substrates (21, 22). Quantitative immunodepletion experiments
demonstrated that these 2 proteins (or associated proteins of similar
sizes) accounted for the bulk of the RPTP
-induced increase in
tyrosine phosphorylation at 90 and 130 kDa (Fig. 5B).
Pharmacological SRC inhibition was used to determine whether the
RPTP
-induced increase in tyrosine phosphorylation of Sin required
SRC activity. As shown in Fig. 5D, the SRC inhibitor PP1,
along with its ability to inhibit neurite outgrowth described above
(Fig. 3B), also reduced tyrosine phosphorylation of Sin to
undetectable levels, indicating that RPTP
-induced phosphorylation of
Sin is fully SRC-dependent.
RPTP
Induces Complex Formation of Sin and Cas with the Adaptors
Crk and Nck--
In fibroblasts, Cas associates with, and is a
substrate, an effector, and an activator of c-SRC (22), controlling
organization of the actin cytoskeleton, cell migration, and activation
of JNK kinases (21, 41, 42). Sin (Efs), whose expression is more restricted than Cas, was isolated in independent screens as a ligand
for the SH3 domains of both SRC (38) and Fyn (43). A third mammalian
member of this family, HEF-1, was isolated on the basis of its ability
to induce pseudohyphal growth in yeast (21). All three share a common
domain structure consisting of an SH3 domain, a "substrate" domain
containing tyrosine phosphorylated SH2 binding sites, a proline-rich
region, and a C-terminal domain with SH3 and SH2 consensus binding
sites for SFKs (Fig. 6A) (21). Their association with cytoplasmic tyrosine kinases is followed by
phosphorylation of the substrate region and ensuing recruitment of
adaptors and other signaling proteins, leading to assembly of higher
order complexes with the potential for interactions between associated
effectors (21). RPTP
enhanced such recruitment of the adaptor CrkL
to Sin and Cas, as shown by analysis of anti-CrkL immune precipitations
from control and wt RPTP
-expressing cells by anti-Cas or anti-Sin
immunoblotting (Fig. 5C). Similar results were obtained for
CrkII (which is less abundant in PC12 cells than CrkL (44); not shown)
and for Nck (Fig. 5C). Consistent with the ability of the
SRC inhibitor PP1 to antagonize the increase in tyrosine
phosphorylation of Sin that is induced by RPTP
(Fig. 5D),
PP1 also reversed the increase in RPTP
-induced complex formation between Sin or Cas and CrkL (Fig. 5E).

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 6.
RPTP /SRC-dependent neurite
extension requires tyrosine phosphorylation of Sin and Crk.
A, schematic diagram of the Cas, Sin, and SinSD proteins.
SR, substrate region containing phosphorylatable tyrosines
that constitute binding sites for adaptors; PL, proline-rich
SRC-SH3 binding sites; Y, tyrosine motif constituting a
SRC-SH2 binding site; C, C-terminal region of homology
between Cas and Sin (21). B, expression of SinSD interferes
with tyrosine phosphorylation of endogenous Sin. Parental cells and
cells expressing wt RPTP or RPTP Y798F were infected with control
(vector (V)) or SinSD-expressing virus. Total lysates
(TL) were analyzed by immunoblotting (IB) with
anti-RPTP (upper) and with anti-Sin (second
panel from top). Anti-Sin immune precipitates
(IP) were analyzed by immunoblotting with
anti-phosphotyrosine (third panel from top) and
with anti-Sin (bottom panel). C, SinSD blocks
neuritogenesis of RPTP -expressing cells in response to EGF. Pools of
cells expressing wt RPTP or RPTP Y798F in the absence of presence
of SinSD were exposed to EGF, and average neurite length (expressed in
cell diameters) was measured after 48 h. Error bars
denote 95% confidence intervals; Statistical significance for
SinSD-infected RPTP (WT) and SinSD-infected
RPTP (YF) cells was tested with respect to
vector-infected RPTP (WT) cells and vector-infected
RPTP (YF) cells, respectively (***, p < 0.001). D, FGF-induced neurite outgrowth in parental PC12
cells (Uninf.) or cells infected with control empty vector
or a SinSD-expressing retrovirus. E, schematic
representation of dominant-negative CrkR38K, in which a lysine residue
critical for SH2 domain function was mutated to arginine. F,
expression of CrkR38K. Pools of cells expressing wt RPTP
(WT) or RPTP Y798F (YF) were infected with
empty (vector (V)) or CrkIIR38K-encoding retrovirus, and
expression of RPTP and CrkIIR38K was monitored by immunoblotting.
G, CrkR38K blocks neuritogenesis of RPTP -expressing cells
in response to EGF. Cells expressing wt RPTP (left) or
RPTP Y798F (right) in the presence or absence of CrkIIR38K
were exposed to EGF for 48 h, and average neurite length was
measured (**, p < 0.01). Average neurite length in
control (non-Crk)-superinfected RPTP -expressing cells was somewhat
lower than in Fig. 3 due to reduced RPTP expression as a consequence
of superinfection (data not shown).
|
|
Sin-Crk Coupling Is a Necessary Mediator of
RPTP
/SRC-dependent Neuritogenesis--
To test the
functional relevance of increased phosphorylation of Sin as caused by
RPTP
-induced activation of SRC, we designed a mutant, SinSD, which
lacks the substrate region that encompasses the tyrosine residues whose
phosphorylation recruits Crk and Nck (Fig. 6A). By retaining
the binding sites for the SH2 and SH3 domains of SRC and Fyn, we
expected SinSD to compete with endogenous Sin for
association with SRC and, thus, to antagonize assembly of productive
complexes around endogenous Sin. An analogous mutant of Cas has been
successful in elucidating the contributions of Cas to cell
migration (20) and JNK activation in fibroblasts (42).
Parental PC12 cells and wt RPTP
or RPTP
Y798F expressors were
infected with a control or SinSD-expressing retrovirus. As expected, SinSD successfully and specifically interfered with tyrosine
phosphorylation of endogenous Sin (Fig. 6B). No effect of
SinSD was noted on the growth rate or morphology or unstimulated cells
(not shown). However, SinSD interfered with the neuritogenic response of wt RPTP
- and RPTP
Y798F-expressing cells to EGF (Fig. 6C) and of parental PC12 cells to FGF (Fig. 6D).
This indicates that endogenous Sin is a necessary effector for the
ability of RPTP
to convert EGF into a neuritogenic factor and that
normal endogenous Sin function is necessary for optimal FGF-induced
outgrowth. We also observed that Sin overexpression potentiated the
RPTP
effect on EGF-induced neuritogenesis (Ref. 45; data not shown), further consistent with Sin being a limiting effector downstream from
RPTP
-activated c-SRC.
A caveat to the above (and many) dominant negative approaches is that
SinSD may compete for access to c-SRC, not only with endogenous Sin but
also with other SRC substrates. Hence, whereas the result in Fig.
6C actually constitutes powerful additional evidence for the
involvement of SRC (or Fyn) in RPTP
-induced neurite outgrowth in
response to EGF, the effect of SinSD might still merely reflect
displacement of another, more critical but unidentified, SRC substrate.
To alleviate this concern, we asked whether Crk, as a downstream
effector of Sin, would be similarly important for EGF/RPTP
-induced
neuritogenesis. We introduced a CrkII mutant, CrkR38K, into wt RPTP
-
or RPTP
Y798F-expressing cells (Fig. 6F); this mutant
adaptor contains a point mutation in its SH2 domain that abolishes its
ability to associate with tyrosine-phosphorylated docking proteins
(Fig. 6E). It can be expected to interact with the full
range of effectors available to endogenous CrkII but to sequester them
in a complex incapable of associating with endogenous docking proteins
for Crk such as Cas and Sin. The experiment revealed clear
interference of CrkR38K with RPTP
/SRC-dependent
neurite outgrowth (Fig. 6G).
 |
DISCUSSION |
Correlative evidence originally gave rise to the hypothesis that
the qualitative distinction between a non-neuritogenic
versus a neuritogenic response is dictated by quantitative
differences in ERK signaling (1). We observed here conversion of a
non-neuritogenic (EGF) into a neuritogenic factor without alteration in
the extent or kinetics of ERK induction. Moreover, in response to FGF,
wt RPTP
and RPTP
Y798F inhibited ERK activation, yet the latter elicited neurite extension. Our data thus demonstrate that the kinetic
pattern of ERK activation does not constitute a necessary determinant
of growth factor specificity. Potentially related observations have
been made using other approaches, e.g. studying the
synergism between NGF and IL-6 in a particular variant PC12 line (46),
or studying the effect of stable transfection of GTPase-deficient G
protein subunits (47) (however, in the latter case, the effect was
constitutive, not showing the growth factor dependence observed here).
In the present study, we identify SRC-mediated assembly of Sin-Crk
complexes as the "alternative" pathway that contributes to
formation of neuritic processes.
The latter conclusion is based on 1) the well established function of
RPTP
in SRC activation (26, 29, 31-34) (Fig. 2B); 2) the
similar effects of c-SRC (Fig. 1C) and RPTP
(Fig. 3) on EGF-induced neuritogenesis; 3) the fact that pharmacological SRC inhibition abolished the ability of RPTP
to alter the nature of the
response to EGF (Fig. 3B); 4) the similarity between the patterns of
tyrosine phosphorylation induced by RPTP
and c-SRC (Figs.
1B and 5A); 5) the observed
SRC-dependent increase in phosphorylation and Crk binding
of Sin and Cas, two known c-SRC substrates (Fig. 5B); and 6)
the ability of both the dominant-negative SRC substrate SinSD and a
dominant-negative version of the associated adaptor CRK to inhibit
neuritogenesis (Fig. 6, C and F). Although each argument is by itself subject to alternative interpretations, taken
together they strongly implicate the cascade SRC > Sin > Crk as a signaling cassette capable of contributing to neurite outgrowth. Notwithstanding the wealth of previous evidence implicating SRC in neurite formation, the identity of its downstream effectors had
remained surprisingly enigmatic; to our knowledge, the present demonstration of the role of Sin-Crk complexes constitutes the first
elucidation of the mechanism of action of SFKs in this process. We
consistently noted that expression of dominant negative versions of Sin
or Crk reduced RPTP
/EGF- or FGF-induced neurite outgrowth but did
not altogether abolish it (Fig. 6, C, D, and
G). Further study will determine whether this reflects an
only partial dominant negative effect (for instance because of an
inability to achieve insufficient expression levels of SinSD or
Crk-R38K) or, more interestingly, reflects the existence and function
of alternative effectors (other than Sin) downstream of SRC that
function in neurite outgrowth.
Docking of Crk to Cas, a close homolog of Sin, is a crucial signaling
step in fibroblast migration, acting in an ERK-independent manner
(19-21, 23), and PTPs that dephosphorylate Cas also severely affect
cell migration (28). Given the mechanistic analogies between migration
and neurite extension, the contribution of related scaffolding proteins
and effector pathways to the latter would thus not seem implausible,
yet had thus far not been recognized.
The pathway outlined above needs to be qualified in two ways. First, it
is unclear to what extent the effects observed occur through activation
of SRC versus Fyn. Although RPTP
regulates both kinases
(30, 33, 34), the role of Fyn in PC12 cells is a totally unexplored
issue that may require further study; however, because Sin is a
common substrate for both (38, 43), it may constitute a point of
convergence. Second, we have not been able to dissect with reasonable
certainty the respective contributions of Cas versus Sin.
Given their similarity, antibody cross-reaction, common binding
partners, and ability to heterodimerize (21, 48), resolution of this
issue will have to rely on reagents as yet to be developed, such as
cell lines that are null for either.
Strikingly, wt RPTP
potentiated the neuritogenic capacities of EGF
but inhibited FGF-dependent neuritogenesis (36). The latter
function likely results from a separate ability of RPTP
to impair
FGF-induced ERK activation, which offsets the
neuritogenesis-stimulating effect of activating the SRC-Sin-Crk
pathway. Two arguments suggest that this inhibitory effect of RPTP
on FGF signaling involves a non-SRC substrate for RPTP
that is
important only for FGF/NGF-mediated outgrowth. First, c-SRC
overexpression mimicked the stimulating effect of RPTP
on EGF
responsiveness but not its inhibitory effect on FGF responsiveness
(Fig. 1C versus Fig. 3A). Hence, the
effect of RPTP
on FGF signaling must diverge from that on EGF
responsiveness upstream of SRC. Second, the two functions could be
mutationally separated; the ability of RPTP
to inhibit FGF-induced
outgrowth is dependent on its Tyr-798 phosphorylation site, but its
outgrowth-eliciting ability in response to EGF is not. Thus, abolishing
the ability of RPTP
to be phosphorylated (the Y798F mutation)
converts RPTP
from an inhibitor to a net stimulator of FGF-induced
neurite outgrowth (most likely due to an additive effect of enhanced
Sin-Crk signaling) and further potentiates the ability of RPTP
to
induce neurite outgrowth in response to EGF. We suggest that
phosphorylation of Tyr-798 in RPTP
is necessary for the ability of
RPTP
to dephosphorylate a substrate in the pathway from the FGF
receptor to ERK activation. Such modulation of the substrate
specificity of RPTP
by Tyr-798 phosphorylation could occur in
various ways, e.g. displacement (as described for the
RPTP
-Tyr-798/SRC-SH2 interaction in fibroblasts (26); but see
below), RPTP
-bound Grb2 acting as an adaptor mediating recruitment
of a specific substrate to RPTP
, or altered RPTP
intracellular
localization (37).
Zheng et al. (31), and den Hertog et al. (32)
reported 3-6-fold and 4-6-fold increases in SRC kinase activity
following RPTP
overexpression. The comparatively more modest
(2-fold; Fig. 2) effect of RPTP
on c-SRC activity seen here in PC12
cells may reflect a more modest level of RPTP
overexpression in the
present case or, alternatively, may be an intrinsic feature of PC12
cells. De-phosphorylation of Tyr-527 activates c-SRC 10-20-fold (49). However, increases of this magnitude in total cellular SRC activity are
never observed. Rather, increases in overall cellular SRC activity that
are of physiological significance tend to be much more modest, in all
probability reflecting activation of only a distinct subpopulation of
the total content of cellular SRC. EGF and NGF were reported to
increase tyrosine phosphorylation of c-SRC by a few fold (50).
Determining to what extent the RPTP
-activated and growth
factor-activated SRC pools may be related or overlapping should be an
area of detailed and careful further analysis.
Although mutation of Tyr-798 abolished the ability of RPTP
to
inhibit FGF-dependent outgrowth, we observed it to have
only minor effects on the ability of RPTP
to activate SRC. Thus, wt RPTP
and RPTP
Y798F both enhanced in vitro SRC kinase
activity (Fig. 2B), in vivo phosphorylation of
the SRC substrate Sin (Fig. 5), and EGF-dependent neurite
outgrowth itself (Fig. 3). We have tried to quantitate the effect of
the Y798F mutation precisely enough so as to be able to document small
effects of it on SRC activation or on tyrosine phosphorylation of Sin.
These experiments (not shown) suggested that the slightly lower SRC
activation by RPTP
Y798F as compared with wt RPTP
(Figs.
2B, and 5A) in part reflects the somewhat lower
level of expression of the RPTP
Y798F mutant protein. Our data differ
from those of Zheng et al. (26), who observed that SRC
activation by RPTP
in fibroblasts is highly dependent on the Tyr-798
phosphorylation site in RPTP
(to displace the Tyr-527 substrate site
from the SRC SH2 domain) (26). Possibly, in PC12 cells, SRC SH2
displacement can be already efficiently mediated by other means
(perhaps involving Sin itself (24)), rendering the contribution of
tyrosine-phosphorylated Tyr-798 in RPTP
less rate-limiting.
Signaling downstream of SRC, Cas, and Sin is thought to rely on the
small GTPase Rap1 (24). Although Crk-mediated Rap1 activation is itself
implicated in sustained ERK activation (44), our data argue for a
contribution of Crk separate from this role. A worthwhile avenue for
further dissection of the mechanism of control of neurite outgrowth by
Sin-Crk coupling may involve the contribution of Rac-like small G
proteins. The controlling role of Cas-Crk complexes in fibroblast
motility has been shown to depend on this pathway (20). DOCK180,
recruited by Crk, activates Rac1 (51), which could thus exert localized
effects on the actin cytoskeleton. Rac and Cdc42 stimulate filopodia
and lamellipodia in the growth cone of neuronal cells, and a balance
between Rho-like and other small G protein activities may control
neurite outgrowth (52). The viral v-Crk oncogene has been shown to
control Rho and to modulate axonal growth in vitro and
in vivo (53, 54).
SRC activity and Cas phosphorylation are induced in response to
cell-cell contact (55) and membrane depolarization (56). We suggest
that neuritogenic signaling by the SRC > Sin-Cas > Crk
cassette may be particularly relevant for stimuli that rely heavily on
SFKs for promoting neurite outgrowth, such as cell-cell adhesion
molecules (8, 9). Indeed, RPTP
localizes to areas of cell-cell
contact (Fig. 2), and several cell-cell adhesion molecules interact
with PTPs in neuronal cells (28, 57); particularly, glycosylphosphatidylinositol-linked contactin associates in cis with RPTP
and the SFK Fyn (11). We have thus far not observed clear
effects of selected cell-cell adhesion or extracellular matrix
molecules or growth factors on the total level of Sin
phosphorylation (data not shown); very likely this issue will require a
detailed one-by-one analysis of phosphorylation sites in Sin. At any
rate, a role for SRC > Sin-Cas > Crk signaling in
specifying neurite outgrowth may help solve two paradoxes associated
with the concept of sustained ERK activation as necessary and
sufficient for neurite outgrowth (1). First, given the complex
multiplicity of neural cell types, "process extension" would not be
expected to be a unitary event, making reliance on a single pathway
unlikely (3, 7). Second, the ability of cells to elaborate multiple
processes with different and plastic properties demands control
mechanisms that can act locally. A role for SRC, whose localization and
activity are tightly regulated, in assembly of localized signaling
complexes around scaffolding proteins such as Sin or Cas may be
relevant in this respect.
 |
ACKNOWLEDGEMENTS |
We thank M. Chao and I. Lax for comments and
A. Bouton, B. Mayer, T. Parsons, E. Skolnik, and D. Unutmaz for reagents.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant CA68365, a grant from the American Heart Association (New York City affiliate), and a Hirschl career scientist award.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The on-line version of this article (available at
http://www.jbc.org) contains a supplemental figure.
¶
To whom correspondence should be addressed.: Dept. of
Pharmacology, New York University School of Medicine, 550 First Ave., New York, NY 10016. Tel.: 212-263-7120; Fax: 212-263-7133; E-mail: jan.sap@med.nyu.edu.
Published, JBC Papers in Press, February 26, 2002, DOI 10.1074/jbc.M111902200
 |
ABBREVIATIONS |
The abbreviations used are:
ERK, extracellular
signal-regulated kinase;
EGF, epidermal growth factor;
FGF, fibroblast
growth factor;
NGF, nerve growth factor;
PTP, protein-tyrosine
phosphatase;
RPTP, receptor protein tyrosine phosphatase;
SFK, SRC
family kinase;
wt, wild type.
 |
REFERENCES |
| 1.
|
Marshall, C. J.
(1995)
Cell
80,
179-185[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Peng, X.,
Greene, L. A.,
Kaplan, D. R.,
and Stephens, R. M.
(1995)
Neuron
15,
395-406[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Vaillancourt, R. R.,
Heasley, L. E.,
Zamarripa, J.,
Storey, B.,
Valius, M.,
Kazlauskas, A.,
and Johnson, G. L.
(1995)
Mol. Cell. Biol.
15,
3644-3653[Abstract]
|
| 4.
|
Alema, S.,
Casalbore, P.,
Agostini, E.,
and Tato, F.
(1985)
Nature
316,
557-559[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Kremer, N. E.,
D'Arcangelo, G.,
Thomas, S. M.,
DeMarco, M.,
Brugge, J. S.,
and Halegoua, S.
(1991)
J. Cell Biol.
115,
809-819[Abstract/Free Full Text]
|
| 6.
|
Rusanescu, G., Qi, H.,
Thomas, S. M.,
Brugge, J. S.,
and Halegoua, S.
(1995)
Neuron
15,
1415-1425[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Kuo, W. L.,
Chung, K. C.,
and Rosner, M. R.
(1997)
Mol. Cell. Biol.
17,
4633-4643[Abstract]
|
| 8.
|
Ignelzi, M. A. j.,
Miller, D. R.,
Soriano, P.,
and Maness, P.
(1994)
Neuron
12,
873-884[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Beggs, H. E.,
Soriano, P.,
and Maness, P. F.
(1994)
J. Cell Biol.
127,
825-833[Abstract/Free Full Text]
|
| 10.
|
Beggs, H. E.,
Baragona, S. C.,
Hemperly, J. J.,
and Maness, P. F.
(1997)
J. Biol. Chem.
272,
8310-8319[Abstract/Free Full Text]
|
| 11.
|
Zeng, L.,
D'Alessandri, L.,
Kalousek, M. B.,
Vaughan, L.,
and Pallen, C. J.
(1999)
J. Cell Biol.
147,
707-714[Abstract/Free Full Text]
|
| 12.
|
Helmke, S.,
Lohse, K.,
Mikule, K.,
Wood, M. R.,
and Pfenninger, K. H.
(1998)
J. Cell Sci.
111,
2465-2475[Abstract]
|
| 13.
|
Boyer, B.,
Roche, S.,
Denoyelle, M.,
and Thiery, J. P.
(1997)
EMBO J.
16,
5904-5913[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Fincham, V. J.,
and Frame, M. C.
(1998)
EMBO J.
17,
81-92[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Stofega, M. R., Yu, C. L., Wu, J.,
and Jove, R.
(1997)
Cell Growth Differ.
8,
113-119[Abstract]
|
| 16.
|
Hakak, Y.,
and Martin, G. S.
(1999)
Mol. Cell. Biol.
19,
6953-6962[Abstract/Free Full Text]
|
| 17.
|
Aftab, D. T.,
Kwan, J.,
and Martin, G. S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3028-3033[Abstract/Free Full Text]
|
| 18.
|
Oldham, S. M.,
Cox, A. D.,
Reynolds, E. R.,
Sizemore, N. S.,
Coffey, R. J., Jr.,
and Der, C. J.
(1998)
Oncogene
16,
2565-2573[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Cary, L. A.,
Han, D. C.,
Polte, T. R.,
Hanks, S. K.,
and Guan, J. L.
(1998)
J. Cell Biol.
140,
211-221[Abstract/Free Full Text]
|
| 20.
|
Klemke, R. L.,
Leng, J.,
Molander, R.,
Brooks, P. C.,
Vuori, K.,
and Cheresh, D. A.
(1998)
J. Cell Biol.
140,
961-972[Abstract/Free Full Text]
|
| 21.
|
O'Neill, G. M.,
Fashena, S. J.,
and Golemis, E. A.
(2000)
Trends Cell Biol.
10,
111-119[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Honda, H.,
Oda, H.,
Nakamoto, T.,
Honda, Z.,
Sakai, R.,
Suzuki, T.,
Saito, T.,
Nakamura, K.,
Nakao, K.,
Ishikawa, T.,
Katsuki, M.,
Yazaki, Y.,
and Hirai, H.
(1998)
Nat. Genet.
19,
361-365[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Yano, H.,
Uchida, H.,
Iwasaki, T.,
Mukai, M.,
Akedo, H.,
Nakamura, K.,
Hashimoto, S.,
and Sabe, H.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
9076-9081[Abstract/Free Full Text]
|
| 24.
|
Xing, L., Ge, C.,
Zeltser, R.,
Maskevitch, G.,
Mayer, B. J.,
and Alexandropoulos, K.
(2000)
Mol. Cell. Biol.
20,
7363-7377[Abstract/Free Full Text]
|
| 25.
|
Schwartzberg, P. L.
(1998)
Oncogene
17,
1463-1468[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Zheng, X. M.,
Resnick, R. J.,
and Shalloway, D.
(2000)
EMBO J.
19,
964-978[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Burnham, M. R.,
Bruce-Staskal, P. J.,
Harte, M. T.,
Weidow, C. L., Ma, A.,
Weed, S. A.,
and Bouton, A. H.
(2000)
Mol. Cell. Biol.
20,
5865-5878[Abstract/Free Full Text]
|
| 28.
|
Petrone, A.,
and Sap, J.
(2000)
J. Cell Sci.
113,
2345-2354[Abstract]
|
| 29.
|
Harder, K. W.,
Moller, N. P. H.,
Peacock, J. W.,
and Jirik, F. R.
(1998)
J. Biol. Chem.
273,
31890-31900[Abstract/Free Full Text]
|
| 30.
|
Bhandari, V.,
Lim, K. L.,
and Pallen, C. J.
(1998)
J. Biol. Chem.
273,
8691-8698[Abstract/Free Full Text]
|
| 31.
|
Zheng, X. M.,
Wang, Y.,
and Pallen, C. J.
(1992)
Nature
359,
336-339[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
den Hertog, J.,
Pals, C. E. G. M.,
Peppelenbosch, M.,
Tertoolen, L. G. J., De,
Laat, S. W.,
and Kruijer, W.
(1993)
EMBO J.
12,
3789-3798[Medline]
[Order article via Infotrieve]
|
| 33.
|
Ponniah, S.,
Wang, D. Z.,
Lim, K. L.,
and Pallen, C. J.
(1999)
Curr. Biol.
9,
535-538[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Su, J.,
Muranjan, M.,
and Sap, J.
(1999)
Curr. Biol.
9,
505-511[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
den Hertog, J.,
Tracy, S.,
and Hunter, T.
(1994)
EMBO J.
13,
3020-3032[Medline]
[Order article via Infotrieve]
|
| 36.
|
Su, J.,
Yang, L.-T.,
and Sap, J.
(1996)
J. Biol. Chem.
271,
28026-28096
|
| 37.
|
Lammers, R.,
Lerch, M. M.,
and Ullrich, A.
(2000)
J. Biol. Chem.
275,
3391-3396[Abstract/Free Full Text]
|
| 38.
|
Alexandropoulos, K.,
and Baltimore, D.
(1996)
Genes Dev.
10,
1341-1355[Abstract/ |